Wadsworth E, Craft S, Calder R, Hammond D. Prevalence and use of cannabis products and routes of administration among youth and young adults in Canada and the United States: a systematic review. Addict Behav. 2022;129:107258.

Article  PubMed  Google Scholar 

Rotermann M. Looking back from 2020, how cannabis use and related behaviours changed in Canada. Health Rep. 2021;32:3–14.

PubMed  Google Scholar 

Carnide N, Nadalin V, Mustard C, Severin CN, Furlan AD, Smith PM. Cannabis use among workers with work-related injuries and illnesses: results from a cross-sectional study of workers’ compensation claimants in Ontario, Canada. BMJ Open. 2023;13:e072994.

Article  PubMed  PubMed Central  Google Scholar 

United Nations Office on Drugs and Crime. UNODC World Drug Report 2022 highlights trends on cannabis post-legalization, environmental impacts of illicit drugs, and drug use among women and youth. United Nations: Office on Drugs and Crime. 2021. www.unodc.org/unodc/en/frontpage/2022/June/unodc-world-drug-report-2022-highlights-trends-on-cannabis-post-legalization--environmental-impacts-of-illicit-drugs--and-drug-use-among-women-and-youth.html. Accessed 3 January (2024).

Wilson-Poe AR, Smith T, Elliott MR, Kruger DJ, Boehnke KF. Past-year use prevalence of cannabidiol, cannabigerol, cannabinol, and Δ8-tetrahydrocannabinol among US adults. JAMA Netw Open. 2023;6:e2347373.

Article  PubMed  PubMed Central  Google Scholar 

Goodman S, Wadsworth E, Schauer G, Hammond D. Use and perceptions of cannabidiol products in Canada and in the United States. Cannabis Cannabinoid Res. 2022;7:355–64.

Article  PubMed  PubMed Central  Google Scholar 

Arnold JC, Nation T, McGregor IS. Prescribing medicinal cannabis. Aust Prescr. 2020;43:152–9.

Article  PubMed  PubMed Central  Google Scholar 

Han BH, Palamar JJ. Trends in Cannabis use among older adults in the United States, 2015–2018. JAMA Intern Med. 24 February 2020. https://doi.org/10.1001/jamainternmed.2019.7517.

McCartney D, Arkell TR, Irwin C, McGregor IS. Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: a systematic and meta-analytic review. Neurosci Biobehav Rev. 2021;126:175–93.

Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G. Cognition and motor control as a function of Δ9-THC concentration in serum and oral fluid: Limits of impairment. Drug Alcohol Depend. 2006;85:114–22.

Article  CAS  PubMed  Google Scholar 

Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017;2:139–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, et al. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: a randomized, double-blind, controlled trial. Epilepsy Behav. 2018;88:162–71.

Article  PubMed  Google Scholar 

Spindle TR, Cone EJ, Goffi E, Weerts EM, Mitchell JM, Winecker RE, et al. Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. Drug Alcohol Depend. 2020;211:107937.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hinton D, Asher T. Organizational policies addressing cannabidiol use in the workplace. Int J Appl Technol Leadersh. 2022;1:1–28.

Levitt H, Sheikh S. Cannabis Is Still a Hazy Workplace Issue in Canada, Years After Legalization. SHRM. 2022. https://www.shrm.org/resourcesandtools/hr-topics/global-hr/pages/canada-cannabis-years-after-legalization.aspx. Accessed 22 September (2023).

MacCallum CA, Lo LA, Boivin M. “Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations. Eur J Intern Med. 2021;89:10–14.

MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–9.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Article  PubMed  PubMed Central  Google Scholar 

Potvin S, Pelletier J, Grot S, Hébert C, Barr AM, Lecomte T. Cognitive deficits in individuals with methamphetamine use disorder: a meta-analysis. Addict Behav. 2018;80:154–60.

Article  PubMed  Google Scholar 

Vandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, et al. Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes. J Anal Toxicol. 2017;41:83–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zamarripa CA, Vandrey R, Spindle TR. Factors that impact the pharmacokinetic and pharmacodynamic effects of cannabis: a review of human laboratory studies. Curr Addict Rep. 2022;9:608–21.

Article  Google Scholar 

Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol. 2013;4:863.

Cohen J. A power primer. Psychol Bull. 1992;112:155–9.

Article  CAS  PubMed  Google Scholar 

Borenstein M, editor. Introduction to meta-analysis. Chichester, U.K: John Wiley & Sons; 2009.

Hedges LV, Tipton E, Johnson MC. Robust variance estimation in meta-regression with dependent effect size estimates. Res Synth Methods. 2010;1:39–65.

Article  PubMed  Google Scholar 

Tipton E. Small sample adjustments for robust variance estimation with meta-regression. Psychol Methods. 2015;20:375–93.

Article  PubMed  Google Scholar 

Fisher Z, Tipton E. robumeta: An R-package for robust variance estimation in meta-analysis. arXiv. 2015;1503.02220.

Viechtbauer W. Conducting meta-analyses in R with the metafor Package. J Stat Soft. 2010;36:1–48.

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.

Article  PubMed  Google Scholar 

Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG. Effect of cannabidiol and Δ 9 -tetrahydrocannabinol on driving performance: a randomized clinical trial. JAMA. 2020;324:2177.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arout CA, Haney M, Herrmann ES, Bedi G, Cooper ZD. A placebo-controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans. Br J Clin Pharm. 2022;88:347–55.

Article  CAS  Google Scholar 

Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O’Carroll C, et al. Modulation of mediotemporal and ventrostriatal function in humans by Δ9-tetrahydrocannabinol: a neural basis for the effects of cannabis sativa on learning and psychosis. Arch Gen Psychiatry. 2009;66:442–51.

Article  CAS  PubMed  Google Scholar 

Bhattacharyya S, Crippa JA, Allen P, Martin-Santos R, Borgwardt S, Fusar-Poli P, et al. Induction of psychosis byΔ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry. 2012;69:27–36.

Article  CAS  PubMed  Google Scholar 

Bloomfield MAP, Green SF, Hindocha C, Yamamori Y, Yim JLL, Jones APM, et al. The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: an arterial spin labelling magnetic resonance imaging study. J Psychopharmacol. 2020;34:981–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML, et al. Neural basis of Δ-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry. 2008;64:966–73.

Article  CAS  PubMed  Google Scholar 

Consroe P, Carlini EA, Zwicker AP, Lacerda LA. Interaction of cannabidiol and alcohol in humans. Psychopharmacology. 1979;66:45–50.

Article  CAS  PubMed  Google Scholar 

Hindocha C, Freeman TP, Grabski M, Crudgington H, Davies AC, Stroud JB, et al. The effects of cannabidiol on impulsivity and memory during abstinence in cigarette dependent smokers. Sci Rep. 2018;8:7568.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hotz J, Fehlmann B, Papassotiropoulos A, De Quervain DJF, Schicktanz NS. Cannabidiol enhances verbal episodic memory in healthy young participants: a randomized clinical trial. J Psychiatr Res. 2021;143:327–33.

Article  PubMed  Google Scholar 

McCartney D, Suraev AS, Doohan PT, Irwin C, Kevin RC, Grunstein RR, et al. Effects of cannabidiol on simulated driving and cognitive performance: a dose-ranging randomised controlled trial. J Psychopharmacol. 2022;36:1338–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry. 2018;8:181.

Article  PubMed  PubMed Central  Google Scholar 

O’Neill A, Wilson R, Blest-Hopley G, Annibale L, Colizzi M, Brammer M, et al. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis. Psychol Med. 2021;51:596–606.

Article  PubMed  Google Scholar 

Solowij N, Broyd S, Greenwood L, Van Hell H, Martelozzo D, Rueb K, et al. A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. Eur Arch Psychiatry Clin Neurosci. 2019;269:17–35.

Article  PubMed  Google Scholar 

van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019;160:860–9.

Article  PubMed  Google Scholar 

Bergamaschi MM, Queiroz RHC, Chagas MHN, de Oliveira DCG, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36:1219–26.

Article  CAS